Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Published: December 02, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws.
Read More
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now trading at a forward P/E of 13.5x, well below historical and sector averages, presenting a de-risked entry point. Zaltenibart targets rare, high-value indications like PNH and complement-mediated nephropathies, offering multi-billion dollar TAM if Phase 3 data prove compelling.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Read More
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Published: November 26, 2025 by: CNBC
Sentiment: Neutral
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
Read More
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
Read More
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Published: November 25, 2025 by: Benzinga
Sentiment: Neutral
Novo Nordisk A/S (NYSE: NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.
Read More
Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains the market leader in obesity and diabetes treatments, despite a recent sharp stock drop and failed Alzheimer's trial. The real growth catalyst for NVO is the upcoming oral semaglutide, which addresses major barriers like affordability and injection aversion. NVO is ahead of Eli Lilly in bringing an oral GLP-1 drug to market, with superior efficacy and a likely 2026 US launch.
Read More
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
Published: November 25, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.
Read More
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
Read More
What's Happening With Novo Nordisk Stock?
Published: November 25, 2025 by: Forbes
Sentiment: Negative
Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Read More
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
Published: November 25, 2025 by: Barrons
Sentiment: Positive
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
Read More
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Published: November 24, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Read More
Top Stock Movers Now: Alphabet, Tesla, Carvana, Novo Nordisk, and More
Published: November 24, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes climbed Monday afternoon as tech stocks rallied, and as optimism about a rate cut by the Federal Reserve next month grew. The Dow rose 0.4% and the S&P 500 added 1.3%, while the tech-heavy Nasdaq surged over 2%.
Read More
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
Published: November 24, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Read More
Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goal
Published: November 24, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) fell sharply on Monday after the Danish pharmaceutical giant said a late-stage trial testing its diabetes and weight-loss drug semaglutide in Alzheimer's disease did not meet its main objective. The Phase III Evoke and Evoke+ trials, which enrolled nearly 3,800 patients with early signs of cognitive decline, showed no meaningful impact on disease progression, Novo Nordisk said.
Read More
Failing Drug Stock Suffers Another Blow on Drug Trial Data
Published: November 24, 2025 by: Schaeffers Research
Sentiment: Negative
Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide.
Read More
Novo Nordisk stock slides as its Alzheimer's drug trials fail
Published: November 24, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.
Read More
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
Read More
3 Weight-Loss Drug Stocks To Consider For 2026
Published: November 21, 2025 by: Benzinga
Sentiment: Positive
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
Published: November 21, 2025 by: WSJ
Sentiment: Positive
Plus, new hormone therapy guidelines, breast-cancer pills and obesity drug price cuts, in this edition of the WSJ Health newsletter.
Read More
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.
Read More
Novo Nordisk: Will Wegovy And Pipeline Spark Rally?
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 billion in the 3rd quarter. Yes, Ozempic remains a "dark spot" in Novo Nordisk's GLP-1 franchise, but at the same time, its sales grew by 3.2% year on year.
Read More
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Published: November 19, 2025 by: MarketBeat
Sentiment: Negative
For investors in Novo Nordisk NYSE: NVO, 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting competitive pressures and concerns about slowing growth in its key GLP-1 franchise.
Read More
Novo Nordisk: A Rare Second Chance
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered guidance, and intensifying competition, but double-digit growth and strong pipeline remain intact. Valuation is compelling: Novo Nordisk trades near its lowest P/E in 20 years and offers a solid free cash flow yield, with intrinsic value estimates well above current price.
Read More
Novo Holdings to sell 7.8% stake in UK's Convatec, bookrunner says
Published: November 17, 2025 by: Reuters
Sentiment: Neutral
Novo Holdings, which controls obesity drugmaker Novo Nordisk , will sell 155 million shares, or about 7.8% of its stake, in British medical products maker Convatec Group , a bookrunner for the offering said on Monday.
Read More
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Read More
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Published: November 17, 2025 by: Barrons
Sentiment: Negative
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406